Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells

Oncogene

Volumn 35, Issue 16, 2016, Pages 2031-2039

  Calabretta, S ^a,b   Bielli, P ^c   Passacantilli, I ^a,b   Pilozzi, E ^b   Fendrich, V ^d   Capurso, G ^b   Delle Fave, G ^b   Sette, C ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; GEMCITABINE; MESSENGER RNA PRECURSOR; POLYPYRIMIDINE TRACT BINDING PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN 1; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; PTBP1 PROTEIN, HUMAN;

ADENOCARCINOMA CELL LINE; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE SILENCING; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM EXPOSURE; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECURRENCE FREE SURVIVAL; UPREGULATION; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; PANCREATIC NEOPLASMS; POLYPYRIMIDINE TRACT-BINDING PROTEIN; PYRUVATE KINASE;

EID: 84938629534     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.270     Document Type: Article

References (51)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-1672.
2. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013; 62: 317-326.
3. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
4. Tang SC, Chen YC. Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 2014; 20: 10825-10844.
5. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
6. Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 2013; 3: 1228-1237.
7. Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, Ghigna C. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol 2013; 2013: 962038.
8. Sette C, Ladomery M, Ghigna C. Alternative splicing: role in cancer development and progression. Int J Cell Biol 2013; 2013: 421606.
9. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136: 777-793.
10. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 2005; 20: 881-890.
11. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193.
12. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al. Cancerassociated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670-676.
13. Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C et al. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNAbinding protein Sam68. Cancer Res 2010; 70: 229-239.
14. Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun 2014; 5: 4581.
15. Dutertre M, Sanchez G, Barbier J, Corcos L, Auboeuf D. The emerging role of premessenger RNA splicing in stress responses: sending alternative messages and silent messengers. RNA Biol 2011; 8: 740-747.
16. Busà R, Geremia R, Sette C. Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin. Nucleic Acids Res 2010; 38: 3005-3018.
17. Paronetto MP, Miñana B, Valcárcel J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol Cell 2011; 43: 353-368.
18. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67: 2072-2080.
19. Naro C, Sette C. Phosphorylation-mediated regulation of alternative splicing in cancer. Int J Cell Biol 2013; 2013: 151839.
20. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011; 20: 768-780
21. Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers 2010; 28: 241-251.
22. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
23. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685-696.
24. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L et al. EGFR-induced and PKC∈ monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 2012; 48: 771-784.
25. Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A et al. SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 2011; 9: 889-900.
26. Droin N, Rébé C, Bichat F, Hammann A, Bertrand R, Solary E. Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene 2001; 20: 260-269.
27. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277: 49374-49382.
28. Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012; 19: 220-228.
29. Proussakova OV, Rabaya NA, Moshnikova AB, Telegina ES, Turanov A, Nanazashvili MG et al. Oligomerization of soluble Fas antigen induces its cytotoxicity. J Biol Chem 2003 Sep; 278: 36236-36241.
30. Nakajima S, Lan L, Wei L, Hsieh CL, Rapić-Otrin V, Yasui A et al. Ubiquitin-specific protease 5 is required for the efficient repair of DNA double-strand breaks. PLoS One 2014; 9: e84899.
31. Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013; 32: 2848-2857.
32. Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V et al. Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. Cell Rep 2014; 7: 501-513.
33. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637-645.
34. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998; 16: 1701-1712.
35. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
36. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res 2012; 18: 5554-5561.
37. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014; 53: 75-87
38. Wang Z, Jeon HY, Rigo F, Bennett CF, Krainer AR. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol 2012; 2: 120133.
39. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 2012; 209: 217-224.
40. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125-140.
41. Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon YS et al. Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell 2009; 36: 996-1006.
42. Carstens RP, Wagner EJ, Garcia-Blanco MA. An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol 2000; 20: 7388-7400.
43. Llorian M, Schwartz S, Clark TA, Hollander D, Tan LY, Spellman R et al. Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB. Nat Struct Mol Biol 2010; 17: 1114-1123.
44. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs 2014; 32: 710-716.
45. Braunschweig U, Gueroussov S, Plocik AM, Graveley BR, Blencowe BJ. Dynamic integration of splicing within gene regulatory pathways. Cell 2013; 152: 1252-1269.
46. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999; 19: 849-851.
47. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 2010; 101: 1447-1453.
48. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093.
49. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 2007; 176: 929-939.
50. Bielli P, Busà R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR et al. The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO Rep 2014; 15: 419-427.
51. Bielli P, Bordi M, Di Biasio V, Sette C. Regulation of BCL-X splicing reveals a role for the Polypyrimidine-tract binding protein (PTBP1/hnRNP I) in alternative 5 'splice site selection. Nucleic Acids Res 2014; 42: 12070-12081.